New HIV pill VH4770359 enters first human safety tests

NCT ID NCT07525544

Recruiting now Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This early-stage study tests a new experimental HIV drug called VH4770359 in 214 healthy adults aged 18-55. The goal is to check its safety, side effects, and how the body processes it. Participants will take either the drug or a placebo, and some will also receive midazolam to see if the new drug interacts with other medicines. Results will help design future studies in people living with HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VH4770359 (an experimental oral antiretroviral drug)
What this could lead to: If successful, this could lead to a new oral medication for controlling HIV, offering another option for people living with the virus.
What could go wrong: This is a very early, first-in-human study in healthy people, not those with HIV. It only tests safety and dosing; it may not work in patients or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Baltimore, Maryland, 21225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.